EDITCAUTIOUS

Revenue Growth (YoY)

-39.2%

Higher than 8% of Healthcare sector peers

Updated 94h ago

Sector Performance

8th percentile

EDIT

-39.2%

Sector Median

6.2%

Sector Avg

3.8%

📊

Deep Analysis

Editas Medicine’s revenue growth year-over-year (YoY) compares its current quarterly revenue to the same quarter one year ago; a decline of -39.2% means revenue has fallen sharply.

This places the company far below the Healthcare sector median of 6.2% growth, ranking in the 8th percentile among peers. The trend data is not available: both the year-over-year change and the quarter-over-quarter change are listed as N/A, and no historical quarterly values or directional pattern exist for the last eight quarters. With a deeply negative revenue growth level and no trend information, the lack of any improving trajectory increases investment risk, as the company is contracting while the sector grows. This metric directly contradicts any positive outlook and supports the overall CAUTIOUS verdict on the stock.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about EDIT?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does EDIT's Revenue Growth (YoY) compare to its sector?

EDIT's Revenue Growth (YoY) of -39.2% compares to a Healthcare sector median of 6.2%, placing it in the 8th percentile.

Who are EDIT's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: TMO (6.2%), AMGN (5.8%), CPRX (5.6%), HIMS (3.8%), BAX (2.9%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.